

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address. COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/889,355	07/08/1997	HEIDRUN ENGLER	16930-000811	3379
7:	590 01/16/2004		EXAM	INER
WILLIAM M			WILSON, M	ICHAEL C
	AND TOWNSEND AND CADERO CNETER	CREW	ART UNIT	PAPER NUMBER
8TH FLOOR	CADERO CIVETER		1632	
SAN FRANCIS	SCO, CA 941113834		DATE MAILED: 01/16/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

IS SET TO EXPIRE 3 N. (a). In no event, however, may a within the statutory minimum of thi 1 apply and will expire SIX (6) MO auses the application to become A late of this communication, even it to be a supply and the supply and the supply apply and the supply apply and the supply apply appl	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communic. BANDONED (35 U.S.C. § 133). If timely filed, may reduce any
Michael C. Wilson ars on the cover sheet w IS SET TO EXPIRE 3 N (a). In no event, however, may a within the statutory minimum of thi l apply and will expire SIX (6) MO ause the application to become A late of this communication, even if tober 2003. ction is non-final. be except for formal mal a parte Quayle, 1935 C.I. attion.	I632 with the correspondence address MONTH(S) FROM reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communic MBANDONED (35 U.S.C. § 133). If timely filed, may reduce any
IS SET TO EXPIRE 3 No. (a). In no event, however, may a within the statutory minimum of this 1 apply and will expire SIX (6) MO auuse the application to become A late of this communication, even in the statutory of the second of the second of this communication, even in the second of the second of this communication, even in the second of the second of this communication, even in the second of the second	with the correspondence address of MONTH(S) FROM I reply be timely filed first (30) days will be considered timely. NITHS from the mailing date of this communic BANDONED (35 U.S.C. § 133). If timely filed, may reduce any
IS SET TO EXPIRE 3 No. (a). In no event, however, may a within the statutory minimum of this lapply and will expire SIX (6) MO auses the application to become A late of this communication, even it stober 2003. Cition is non-final. Dee except for formal mate a parte Quayle, 1935 C. Intion.	MONTH(S) FROM I reply be timely filed Irreply do days will be considered timely. NTHS from the mailing date of this communic. BANDONED (35 U.S.C. § 133). If timely filed, may reduce any tters, prosecution as to the merit
(a). In no event, however, may a vithin the statutory minimum of thi I apply and will expire SIX (6) MO ause the application to become A late of this communication, even if tober 2003. ction is non-final. ce except for formal mal a parte Quayle, 1935 C.I.	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communic. BANDONED (35 U.S.C. § 133). If timely filed, may reduce any
ction is non-final. ce except for formal mal ce parte Quayle, 1935 C.I	
ction is non-final. ce except for formal mal ce parte Quayle, 1935 C.I	
ce except for formal mat <i>parte Quayl</i> e, 1935 C.I ution.	
election requirement.	
on is required if the drawing	b by the Examiner. ance. See 37 CFR 1.85(a). g(s) is objected to. See 37 CFR 1.12 and Office Action or form PTO-152
have been received. have been received in A ty documents have been (PCT Rule 17.2(a)). If the certified copies no priority under 35 U.S.C	Application No n received in this National Stage t received. S 119(e) (to a provisional application or in an Application Data s
i	(PCT Rule 17.2(a)). of the certified copies not priority under 35 U.S.C

Attachment(s)

1) Notice of References Cited (PTO-892)
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 10-20-03
4) Interview Summary (PTO-413) Paper No(s) 5) Notice of Informal Patent Application (PTO-152)
6) Other:

reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Art Unit: 1632

DETAILED ACTION

Applicant's arguments filed 10-20-03 have been fully considered but they are not persuasive. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action. Claims 1-40 and 42-53 have been canceled. Claim 54 has been added. Claims 41 and 54 remain pending in the instant application. The effective filing date of the claimed invention remains July 8, 1997.

Election/Restrictions

Newly submitted claim 54 directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: it is not readily apparent that the structure of 3'-N-gluconamidopropyl-3"-N-cholamidopropyl-N-cholamide as newly claimed is related to the compound originally claimed. The compound of Claim 54 would require a different search not previously required.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 54 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Claim 41 is under consideration in the instant office action.

Claim Rejections - 35 USC § 112

 Claims 41 remains rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention for reasons of record.

Art Unit: 1632

Claim 41 is drawn to a compound wherein X1 and X2 are both cholic acid groups and X3 is a pentose monosaccharide group. The specification teaches isolating Impurities I, II and III from BigCHAP; however, the specification does not describe their structure. Since the time of filing, the structure of Impurities I, II and III have been determined (see Fig. 22, 23 and 24 in US Application 09/112,074, now US Patent 6,392,069).

Impurity I does not correlate to the compound of claim 41 because Impurity I does not have the same tertiary nitrogen as the compound in claim 41.

Impurity III does not correlate to the compound of claim 41 because X1 is a saccharide group in Impurity III while X1 is a cholic acid group in the compound claimed.

Since the time of filing Impuritiy II has been described as a compound having both X1 and X2 as cholic acid groups and X3 as a pentose monosaccharide. The specification as originally filed did not adequately describe Impurity II as a compound having both X1 and X2 as cholic acid groups and X3 as a pentose monosaccharide. Example 12 (pg 31, lines 15-19) illustrates the procedure for making a compund but does not describe the structure of the compound; nor is it readily apparent that Example 12 is synthesizing Impurity II. Page 5, lines 2-10, does not teach both X1 and X2 were cholic acid and X3 was a pentose monosaccharide. Page 6, lines 31-32, merely states that a saccharide group found in a compound of Formula I (as originally filed wherein X1 and X2 had broader scopes) may be a pentose monosaccharide and does not teach or suggest that X1 and X2 are both cholic acid while X3 is a pentose monosaccharide. The structure of Impurity II is not readily apparent from the specification as originally filed because the specific combination of elements in X1, X2 or X3 could not have been guessed based on the broad original description of Formula I and the broad scope of

Art Unit: 1632

possibilities for X1, X2 and X3. Without such guidance, the specification as originally filed did not adequately describe the structure of the compound of claim 41, specifically that the compound had the properties of Impurity II.

While Impurity II is a species within the genus of compounds contemplated as "Formula I" in the specification as originally (see original claim 1), the specific structure of Impurity II and now claimed was not disclosed or readily apparent from the specification. Nor did the specification as originally filed link the ability to increase transfection of nucleic acids into cells found in Impurity II with a compound having a structure as now claimed. An adequate written description of Impurity II requires more than a mere description of the genus of the compound and a statement that Impurity II was isolated and part of the invention. What is required is a description of the structure of Impurity II itself. It is not sufficient to state Impurity II is one of a host of possible combinations of elements because disclosure of no more than that, as in the instant case, is simply a wish to know the identity of the specific structure of Impurity II. Thus, claiming a compound without describing the specific structure of the compound is not in compliance with the description requirement. Rather, it is an attempt to preempt the future before it has arrived. (See Fiers v. Revel, 25 USPQ2d 1601 (CA FC 1993) and Regents of the Univ. Calif. v. Eli Lilly & Co., 43 USPQ2d 1398 (CA FC, 1997)).

Impurity II has a cholic acid group attached at X1 and X2 such that the terminal CO₂H of cholic acid is removed; however, the manner in which cholic acid is attached at X1 and X2 was not disclosed in the specification as originally filed. It is not readily apparent from the description of Impurity II that X1 and X2 were cholic acid with a deletion of the terminal CO₂H. Applicants state a person of skill in the art would have understood Example 12 described a cholic acid group as being a cholic acid without a terminal CO₂H. Applicants' argument is not persuasive. It would not have been readily

Art Unit: 1632

apparent to one of skill in the art what structure would result from the method in Example 12, specifically how cholic acid would attach at X1 and X2 or the structure of cholic acid once it reacts with isobutylchloroformate in the presence of triethylamine. Nor does Example 12 teach Impurity II is the product being synthesized. It would not have been readily apparent to one of skill at the time of filing that the process described in Example 12 results in Impurity II. Example 12 does not describe 3-aminopropyl-3'-Naluconamidopropyl-amine (the product being synthesized) as Impurity II. The specification does not describe Impurity II (isolated in Example 11, pg 28), as 3aminopropyl-3'-N-gluconamidopropyl-amine. It would not have been readily apparent to one of skill in the art that the method in Example 12 made Impurity II or was specific to making only Impurity II. It would not have been readily apparent to one of skill that reacting cholic acid with isobutylchloroformate in the presence of triethylamine described in Example 12 would result in cholic acid without the terminal CO2H. The at the time of filing did not define a "cholic acid group" as being cholic acid without the terminal CO2H. Therefore, the structure of Impurity II being that of claim 41 was not readily apparent to one of skill in the art at the time of filing based on the teachings in the specification as originally filed.

2. Claim 41 remains rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention for reasons of record.

The claim is drawn to a compound having a particular structure wherein X1 and X2 are both cholic acid groups and X3 is a pentose monosaccharide group. The specification teaches isolating Impurities I, II and III from BigCHAP; however, the

Art Unit: 1632

specification does not describe their structure. Since the time of filling, the structure of Impurities I, II and III have been determined (see Fig. 22, 23 and 24 in US Application 09/112,074, now US Patent 6,392,069). BigCHAP and Impurity I do not correlate to the compound of claim 41 because BigCHAP and Impurity I do not have the same tertiary nitrogen as the compound in claim 41. Impurity III does not correlate to the compound of claim 41 because X1 is a saccharide group in Impurity III while X1 is a cholic acid group in the compound claimed.

Since the time of filing Impurity II was described as a compound having both X1 and X2 as cholic acid groups and X3 as a pentose monosaccharide. The specification as originally filed did not distinctuish the structure of Impurities I, II and III, so that one of skill would have known Impurity II had X1 and X2 as cholic acid groups (and not deoxycholic acid group). Nor did the specification teach X3 in Impurity II was a pentose monosaccharide group. Therefore, the structure of Impurity II is not readily apparent from the specification as originally filed because the specific combination of elements in X1, X2 or X3 could not have been guessed. Thus, it would have required one of skill undue experimentation to determine how to make or use the compound claimed as Impurity II. Furthermore, Impurity II has a cholic acid group attached at X1 and X2 such that the terminal CO₂H of cholic acid is removed; however, the manner in which cholic acid is attached at X1 and X2 is not disclosed in the specification. It is not readily apparent from the description of Impurity II that X1 and X2 were cholic acid with a deletion of the terminal CO₂H. Therefore, the structure of Impurity II is not readily apparent from the specification as originally filed because it could not have been guessed that the cholic acid group was attached such that the terminal CO₂H was deleted.

Art Unit: 1632

Applicants' arguments for enablement are the same as those for written description, which are addressed above in the written description rejection.

 Claim 41 remains rejected as being indefinite because the structures encompassed by the claims are unclear for reasons of record.

The claim requires a compound having Formula I, wherein X1 and X2 are both cholic acid groups. The specification (Ex. 11) states three impurities (I, II and III) were isolated from BC BigCHAP, but does not teach the structure of the impurities or how cholic acid is attached to Formula I. The structure of Impurity II has three carbons between the carboxyl group and the pentose ring instead of four in the cholic acid (i.e. Impurity II require X1 and X2 are both a cholic acid group wherein the cholic acid group is cholic acid with a deletion of the terminal CO₂H). Addition of cholic acid to Formula I may result in i) four carbons between the carboxyl group and the pentose ring of the cholic, ii) removal of the carboxyl group, iii) or attachment at one of the hydroxyl groups. Therefore, it is unclear whether applicants intend the claim to encompass any means of attaching cholic acid to Formula I at X1 and X2 or if the claim is limited to removal of the carboxyl group of cholic acid.

Applicants' arguments for 112/2nd are the same as those for written description and enablement, which are addressed above in the written description rejection.

Conclusion

No claim is allowed.

Art Unit: 1632

Inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Wilson who can normally be reached on Monday through Friday from 9:00 am to 5:30 pm at (703) 305-0120. The Examiner's number will be changed on January 12th, 2004 to 571-272-0738.

Questions of a general nature relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

If attempts to reach the examiner, patent analyst or Group receptionist are unsuccessful, the examiner's supervisor, Deborah Reynolds, can be reached on (703) 305-4051.

The official fax number for this Group is (703) 872-9306.

Michael C. Wilson

MICHAEL WILSON PRIMARY EXAMINER